Literature DB >> 26345422

Cancer immunotherapy innovator James Allison receives the 2015 Lasker~DeBakey Clinical Medical Research Award.

Jillian H Hurst.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26345422      PMCID： PMC4607124          DOI： 10.1172/JCI84236

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  52 in total

Review 1.  Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy.

Authors:  R H Schwartz
Journal:  Cell       Date:  1992-12-24       Impact factor: 41.582

2.  CTLA-4 can function as a negative regulator of T cell activation.

Authors:  T L Walunas; D J Lenschow; C Y Bakker; P S Linsley; G J Freeman; J M Green; C B Thompson; J A Bluestone
Journal:  Immunity       Date:  1994-08       Impact factor: 31.745

3.  Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg.

Authors:  D J Lenschow; Y Zeng; J R Thistlethwaite; A Montag; W Brady; M G Gibson; P S Linsley; J A Bluestone
Journal:  Science       Date:  1992-08-07       Impact factor: 47.728

4.  Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

Authors:  J M Kirkwood; M H Strawderman; M S Ernstoff; T J Smith; E C Borden; R H Blum
Journal:  J Clin Oncol       Date:  1996-01       Impact factor: 44.544

5.  Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4.

Authors:  E A Tivol; F Borriello; A N Schweitzer; W P Lynch; J A Bluestone; A H Sharpe
Journal:  Immunity       Date:  1995-11       Impact factor: 31.745

6.  Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells.

Authors:  S E Townsend; J P Allison
Journal:  Science       Date:  1993-01-15       Impact factor: 47.728

7.  Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4.

Authors:  P Waterhouse; J M Penninger; E Timms; A Wakeham; A Shahinian; K P Lee; C B Thompson; H Griesser; T W Mak
Journal:  Science       Date:  1995-11-10       Impact factor: 47.728

8.  Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes.

Authors:  P S Linsley; J L Greene; P Tan; J Bradshaw; J A Ledbetter; C Anasetti; N K Damle
Journal:  J Exp Med       Date:  1992-12-01       Impact factor: 14.307

9.  CD28-B7 interactions allow the induction of CD8+ cytotoxic T lymphocytes in the absence of exogenous help.

Authors:  F A Harding; J P Allison
Journal:  J Exp Med       Date:  1993-06-01       Impact factor: 14.307

10.  CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.

Authors:  M F Krummel; J P Allison
Journal:  J Exp Med       Date:  1995-08-01       Impact factor: 14.307
View more
  6 in total

Review 1.  Immunotherapy of Melanoma: Facts and Hopes.

Authors:  Sarah A Weiss; Jedd D Wolchok; Mario Sznol
Journal:  Clin Cancer Res       Date:  2019-03-28       Impact factor: 12.531

2.  A different type of acute myocarditis: a case report of acute autoimmune myocarditis mediated by anti-PD-1 T lymphocyte receptor (pembrolizumab).

Authors:  Mario Salido Iniesta; Laura López López; Francesc Carreras Costa; Alessandro Sionis
Journal:  Eur Heart J Case Rep       Date:  2020-10-04

Review 3.  Functional genomics: paving the way for more successful cancer immunotherapy.

Authors:  Reham Ajina; Danielle Zamalin; Louis M Weiner
Journal:  Brief Funct Genomics       Date:  2019-03-22       Impact factor: 4.241

Review 4.  PET Radiopharmaceuticals for Imaging Chemotherapy-Induced Cardiotoxicity.

Authors:  Jothilingam Sivapackiam; Monica Sharma; Thomas H Schindler; Vijay Sharma
Journal:  Curr Cardiol Rep       Date:  2020-06-19       Impact factor: 2.931

Review 5.  Factors Determining Long-Term Antitumor Responses to Immune Checkpoint Blockade Therapy in Melanoma.

Authors:  Kimberly Loo; James W Smithy; Michael A Postow; Allison Betof Warner
Journal:  Front Immunol       Date:  2022-01-11       Impact factor: 7.561

Review 6.  Cardiotoxicity of immune checkpoint inhibitors.

Authors:  Gilda Varricchi; Maria Rosaria Galdiero; Giancarlo Marone; Gjada Criscuolo; Maria Triassi; Domenico Bonaduce; Gianni Marone; Carlo Gabriele Tocchetti
Journal:  ESMO Open       Date:  2017-10-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.